Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus Apr 11, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Feb 14, 2022
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion… Nov 23, 2021
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection… Nov 16, 2021
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin… Nov 3, 2021
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India Jun 8, 2021
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip May 17, 2021
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 May 3, 2021
